Source: DGNews  |  Posted 9 years ago

LONDON, ENGLAND -- February 7, 2003 -- New long-term data published in an international medical journal - Epilepsy Research - show that Keppra (levetiracetam) offers sustained efficacy, as add-on, over the longer term - up to 54 months (4.5 years) - in reducing seizure frequency in adult patients with difficult to treat partial seizures. In addition, the data reveal that long-term treatment Keppra remains very well tolerated by the patients.

These data further demonstrate the favourable efficacy and safety profile of Keppra (levetiracetam), confirming its place at the forefront of the management of epilepsy. Keppra is currently indicated as adjunctive treatment of partial onset seizures, with or without secondary generalisation, in adults with epilepsy.

To our knowledge, this is the first and largest ever published study to collate data on patient retention and seizure freedom rates for adults with refractory epilepsy over a long-term (up to 54-month) treatment period. Data from 1,422 patients were analysed for changes in seizure frequency per week, seizure freedom and adverse events.

The lead investigator on this new study is Professor Elinor Ben-Menachem, from the Department of Clinical Neuroscience, Sahlgren University Hospital, G